Contact
Please use this form to send email to PR contact of this press release:
Principia Biopharma Announces PRN1008 Receives Orphan-Drug Designation from FDA for Treatment of Immune Thrombocytopenic Purpura
TO:
Please use this form to send email to PR contact of this press release:
Principia Biopharma Announces PRN1008 Receives Orphan-Drug Designation from FDA for Treatment of Immune Thrombocytopenic Purpura
TO: